Jacob R Greenmyer1, Mira Kohorst2. 1. Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. 2. Pediatric Hematology and Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Kohorst.mira@mayo.edu.
Abstract
PURPOSE OF REVIEW: Juvenile myelomonocytic leukemia (JMML) is a rare but severe pediatric neoplasm with hematopoietic stem cell transplant as its only established curative option. The development of targeted therapeutics for JMML is being guided by an understanding of the pathobiology of this condition. Here, we review JMML with an emphasis on genetics in order to (i) demonstrate the relationship between JMML genotype and clinical phenotype and (ii) explore potential genetic targets of novel JMML therapies. RECENT FINDINGS: DNA hypermethylation studies have demonstrated consistently that methylation is related to disease severity. Increasing understanding of methylation in JMML may open the door to novel therapies, such as DNA methyltransferase inhibitors. The PI3K/AKT/MTOR, JAK/STAT, and RAF/MEK/ERK pathways are being investigated as therapeutic targets for JMML. Future therapy for JMML will be driven by an increased understanding of pathobiology. Targeted therapeutic approaches hold potential for improving outcomes in patients with JMML.
PURPOSE OF REVIEW: Juvenile myelomonocytic leukemia (JMML) is a rare but severe pediatric neoplasm with hematopoietic stem cell transplant as its only established curative option. The development of targeted therapeutics for JMML is being guided by an understanding of the pathobiology of this condition. Here, we review JMML with an emphasis on genetics in order to (i) demonstrate the relationship between JMML genotype and clinical phenotype and (ii) explore potential genetic targets of novel JMML therapies. RECENT FINDINGS: DNA hypermethylation studies have demonstrated consistently that methylation is related to disease severity. Increasing understanding of methylation in JMML may open the door to novel therapies, such as DNA methyltransferase inhibitors. The PI3K/AKT/MTOR, JAK/STAT, and RAF/MEK/ERK pathways are being investigated as therapeutic targets for JMML. Future therapy for JMML will be driven by an increased understanding of pathobiology. Targeted therapeutic approaches hold potential for improving outcomes in patients with JMML.
Authors: F Locatelli; C Niemeyer; E Angelucci; C Bender-Götze; S Burdach; W Ebell; W Friedrich; H Hasle; J Hermann; N Jacobsen; T Klingebiel; B Kremens; G Mann; A Pession; C Peters; H J Schmid; J Stary; M Suttorp; C Uderzo; E T van't Veer-Korthof; J Vossen; M Zecca; M Zimmermann Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: C M Niemeyer; M Arico; G Basso; A Biondi; A Cantu Rajnoldi; U Creutzig; O Haas; J Harbott; H Hasle; G Kerndrup; F Locatelli; G Mann; B Stollmann-Gibbels; E T van't Veer-Korthof; E van Wering; M Zimmermann Journal: Blood Date: 1997-05-15 Impact factor: 22.113
Authors: Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer Journal: Blood Date: 2004-09-07 Impact factor: 22.113
Authors: Franco Locatelli; Alessandro Crotta; Annalisa Ruggeri; Mary Eapen; John E Wagner; Margaret L Macmillan; Marco Zecca; Joanne Kurtzberg; Carmem Bonfim; Ajay Vora; Cristina Díaz de Heredia; Lochie Teague; Jerry Stein; Tracey A O'Brien; Henrique Bittencourt; Adrienne Madureira; Brigitte Strahm; Christina Peters; Charlotte Niemeyer; Eliane Gluckman; Vanderson Rocha Journal: Blood Date: 2013-08-07 Impact factor: 22.113
Authors: Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh Journal: Nat Genet Date: 2015-10-12 Impact factor: 38.330